



Cite this: *Mater. Adv.*, 2023,
4, 2853

Copper iodide microhexagons: a potential therapeutic agent for surface microbial infection and melanoma[†]

Sunil Venkanna Pogu,[‡] Dokkari Nagalaxmi Yadav,[‡] Sri Amruthaa Sankaranarayanan, Rupali Srivastava, Shashidhar Thatikonda  and Aravind Kumar Rengan  *

Microbial infections are a constant threat to humans and responsible for increased death rate in most of the developing countries. Conventional use of chlorine- or alcohol-based disinfectants results in the development of drug-resistant microbial strains, which are limited in their response to most of the treatment strategies. In this perspective, several engineered materials have emerged as an affordable alternative to the existing treatment strategies. For the same, here we have synthesised Cul microparticles (Cul (WH) and Cul (H)) using chemical precipitation followed by a hydrothermal process. We further comparatively evaluated the antiproliferative activity of Cul (WH) and Cul (H) against microbial cultures (non-resistant and resistant), virus, and cancer cell lines. Cul (H) displayed better size, stability, and significantly higher inhibitory activity against microorganisms and cancer cell lines than Cul (WH). Upon preliminary evaluation, which confirmed that Cul (H) is more effective than Cul (WH), we evaluated its stability and surface sterilising property, and it was found that Cul (H) were stable for the recorded period of 30 days and displayed significant surface sterilising ability. The results suggest that Cul (H) is a potent antiproliferative material against microbial cultures, viral strains, and cancer cell lines while preserving its biocompatibility towards normal cell lines, representing a potential surface sterilising material in public places upon significant *in vivo* efficacy evaluation.

Received 7th March 2023,
Accepted 5th June 2023

DOI: 10.1039/d3ma00110e

rsc.li/materials-advances

1. Introduction

Microbial infections are potential health hazards responsible for the major portion of the global mortality rate. These infections could arise due to an unhealthy lifestyle or may be due to accidental exposure to pathogens during post-surgical wound healing.^{1,2} The use of conventional antibiotics to treat microbial infections is limited in clinical outcomes due to the development of multi-drug resistance in microbial strains.^{3–5} Also, antibiotic use leads to various detrimental side effects, such as non-targeted accumulation, tissue toxicity, and renal damage.⁶ It is also reported that the use of chlorine- and alcohol-based surface disinfectants in public places such as hospitals and public transportation leads to the development of resistant strains increasing the chances of exposure to resistant microbes and their associated toxicities.⁷ In 2019, around 8 000 000 people were killed by antibiotic-resistant *E. coli* (*Escherichia coli*) alone.⁸ It is

also found that more than 80% of *E. coli* strains isolated from wounds are antibiotic resistant, making them even more difficult to treat.⁹ During the last three years, viral infections (Covid-19) have devastated the human lifestyle globally and have been a reason for the deaths of millions of people.¹⁰

Along with microbial infections, cancer is also a major disease of concern, responsible for millions of deaths annually.¹¹ Several studies were reported on the interdependence of microbial infections with the emergence of cancer or *vice versa*. Melanoma, in particular, is a predominant type of malignant skin cancer, which arises from premalignant actinic keratoses under chronic inflammation. Wounded and burned areas on the skin are more prone to microbial infections, which further increases the chance of skin cancer development. Microbial infections on skin promote the secretion of inflammatory factors (IL-6, IL-8, and TNF-alpha) and generate ROS (reactive oxygen species), which in turn promote transformation of premalignant actinic keratoses into malignant squamous cell carcinoma.^{12,13} Hence, developing a highly efficient biocompatible material which exhibits potential antimicrobial and anti-cancer activity, and at the same time it is less prone to resistance induction in microbes and cancer cells, is warranted to treat pathogenic infections and associated complications.

Dept of Biomedical Engineering, Indian Institute of Technology Hyderabad, India.
E-mail: aravind@bme.iith.ac.in

[†] Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3ma00110e>

[‡] These authors contributed equally.



Many metallic nano-/microparticles have been reported for various theranostic applications,^{14,15} and are known to be less susceptible to the development of microbial resistance.¹⁶ For a long time, copper vessels have been used to store and serve food and water due to copper metal's intrinsic antiproliferative property, preventing the infectivity of various diseases. Several studies have reported on copper nano-/microparticles having an inhibitory effect against microbial and cancer cell growth.¹⁷⁻¹⁹ Similarly, iodine-based nano-/microparticles have been shown to be effective in inhibiting microbial and tumour growth.^{20,21} Iodine rapidly diffuses into cells through sodium iodide symporters and oxidises proteins, nucleotides, and fatty acids, eventually causing cell death.^{22,23} Recently, iodine nanoparticles were found to be effective in enhancing proapoptotic genes, and these iodine-based materials are also applicable in tumour tissue diagnosis using the computed tomography technique.²⁴ So, here, we hypothesise that forming composite particles consisting of copper and iodine will provide a synergistic effect against microbial and cancer cell growth, as iodine will enhance the antibacterial effect of copper. At the same time, copper will enhance the anticancer effect of iodine. Polymer coating on the metallic nano-/microparticles imparts excellent particle stability and dispersibility. Various polymers such as polyethylene glycol, polyvinylpyrrolidone, and poly(acrylic acid) (PAA) were reported


as a coating materials onto metallic particles, which resulted in increased dispersibility, stability, and targeted tumour accumulation.²⁵⁻²⁸

In the present study, we have synthesised PAA polymer-coated CuI (copper iodide) microparticles using a chemical precipitation method (CuI (WH)) and further subjected them to hydrothermal reaction to obtain CuI (H) microhexagons. The obtained CuI (WH) and CuI (H) were characterised and evaluated for their antiproliferative property against microbial cultures (*Escherichia coli* (*E. coli*), *Staphylococcus aureus* (*S. aureus*), and *Candida albicans* (*C. albicans*)), virus (bacteriophage lambda), and MDR (multidrug-resistant) *E. coli*. CuI (WH) and CuI (H) were then tested for their biocompatibility in a non-cancerous cell line (L929) and their cytotoxic activity against cancer cell lines (4T1, HCT 116, A549, B16) (Scheme 1). Finally, the long-term stability of CuI (H) in aqueous suspension and its application in surface sterilisation were investigated.

2. Materials and methods

2.1 Materials

Copper dichloride (CuCl₂), propidium iodide (PI), fluorescein diacetate (FDA), and PAA were purchased from Sigma-Aldrich.



Scheme 1 An overview of the synthesis and applications of CuI (WH) and CuI (H).



Dulbecco's modified Eagle's medium (DMEM), Roswell Park Memorial Institute medium (RPMI 1640), fetal bovine serum (FBS), pen-strep solution, phosphate-buffered saline (PBS), trypsin EDTA solution, LB (Luria Bertani) agar/broth, MH (Mueller and Hinton) agar/broth, and SD (Sabouraud Dextrose) were purchased from Himedia Laboratories, Mumbai (India). MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), potassium iodide (KI), sodium sulphite (Na_2SO_3), and dimethyl sulfoxide (DMSO) were purchased from SRL Chemicals Ltd (Mumbai, India). All other reagents used were of analytical grade. Ultra-pure de-ionised water (Milli-Q) was used for conducting all the experiments.

2.2 Synthesis and characterisation of CuI (WH) and CuI (H)

CuI particles were synthesised by modifying the procedure reported by Zhou *et al.*²⁹ Briefly, for the synthesis of CuI (WH) particles, 25 mg of CuCl_2 and 400 mg of PAA were dissolved in 20 mL of a 1:1 (water:ethanol) solution and stirred for 10 min at room temperature. After that, an aqueous solution of Na_2SO_3 and KI was added dropwise under stirring, turning the cyan-blue solution into a pale brown and then to an off-white precipitate indicating the formation of CuI (WH). Similarly, for the synthesis of CuI (H), the obtained CuI (WH) precipitate solution was transferred into a Teflon-lined container and heated under pressure at 180 °C for 3.5 hours (hydrothermal process). After that, it was cooled to room temperature. CuI (WH) and CuI (H) were obtained by washing them with ethanol and water. CuI without PAA (CuI (WP)) was also synthesised like CuI (H) without the addition of PAA during the initial procedure.

The fluorescence properties of CuI (WH) and CuI (H) were determined using a UV lamp (365 nm, Analytik Jena, CA, USA) and fluorescence spectrophotometer (RF 6000, Shimadzu, Japan). Absorption spectra were obtained using a UV-visible spectrophotometer (UV 1800, Shimadzu, Japan). The hydrodynamic diameters of the CuI (WH) and CuI (H) particles were determined using a DLS instrument (Particle Sizing Systems, Inc. Santa Barbara, California, USA) and the surface charge on the particles was determined using a Zeta sizer (Particle Sizing Systems, Inc. Santa Barbara, California, USA). The morphology and size of CuI (WH) and CuI (H) microparticles were visualised using a field emission scanning electron microscope (FE-SEM, Carl Zeiss atomic microscope, Supra40 Germany). The elemental composition of CuI (H) was analysed using EDS (energy dispersive X-ray spectroscopy).

2.3 Antibacterial efficacy of CuI (WH) and CuI (H)

The antibacterial activity of the CuI (WH) and CuI (H) particles was evaluated against Gram-negative bacteria (*E. coli*) and Gram-positive bacteria (*S. aureus*).

2.3.1 Bacterial culture & maintenance. *E. coli* was received as a gift sample from Dr Manjula Reddy, CSIR-CCMB (CSIR-Centre for Cellular and Molecular Biology), Hyderabad, India. *S. aureus* culture was obtained from MTCC, India. A single colony of *E. coli* and *S. aureus* on LB Agar plates was isolated and inoculated into LB broth which was incubated at 37 °C until each culture's growth reached an OD (optical density) of

1.0. Then, the cultures were diluted to OD of 0.1 using MH broth for the investigations.³⁰

2.3.2 Evaluation of antibacterial activity using MTT assay.

In a 96-well plate, 100 μL of *E. coli* culture (triplicates) was added and treated with CuI (WH) and CuI (H) at concentrations ranging from 25 $\mu\text{g mL}^{-1}$ to 100 $\mu\text{g mL}^{-1}$, and for the control, MH broth without particles was added. Similarly, 100 μL of *S. aureus* culture (triplicates) was added and treated with CuI (WH) and CuI (H) at a concentration ranging from 50 $\mu\text{g mL}^{-1}$ to 300 $\mu\text{g mL}^{-1}$, and for control, broth without particles was added. After 24 hours of treatment, the percentage cell viability of each bacterium was quantified using the MTT assay.

2.3.3 Evaluation of antibacterial activity using spot formation assay. Spot formation assay determines the size of spot formed by treated and control samples. The more viable the bacteria in the sample, the bigger the size of the spot formed, and *vice versa*. For the investigation of the same, 100 μL of *E. coli* culture in a 96-well plate was treated with 25 $\mu\text{g mL}^{-1}$ to 100 $\mu\text{g mL}^{-1}$ concentration of CuI (WH) and CuI (H) per well, and for control, only broth was added then incubated at 37 °C for 24 h. Similarly, the *S. aureus* culture was treated with 50 $\mu\text{g mL}^{-1}$ to 300 $\mu\text{g mL}^{-1}$ concentrations of CuI (WH) and CuI (H) and incubated at 37 °C for 24 h. After incubation, a spot assay was performed for both bacterial cultures. Briefly, 9-fold serial dilutions were made of the inoculum (10 to 10^{-8}) in a total volume of 1 mL in the treated and control wells, from which 10 μL was taken and spotted onto MH agar plates. After 24 hours of incubation at 37 °C, the difference in colony formation was observed.³¹

2.3.4 Evaluation of antibacterial activity using acridine orange staining. The qualitative visualisation of the effect of CuI (WH) and CuI (H) on the viability of both bacteria strains was determined using acridine orange (AO) staining. Briefly, 100 μL of *E. coli* culture in a 96-well plate was treated with 50 $\mu\text{g mL}^{-1}$ of CuI (H) and CuI (WH) along with the control and incubated at 37 °C for 24 h. Similarly, the *S. aureus* inoculum was treated with 200 $\mu\text{g mL}^{-1}$ of CuI (WH) and CuI (H) along with the control in a 96-well plate and incubated at 37 °C for 24 h. After 24 h of incubation, 10 μL of the control and treated samples were methanol-fixed onto a clean glass slide and then stained with 0.01% AO solution for 2 min.^{32,33} The extra stain on the slide was removed and washed with PBS and then imaged under blue light using a fluorescent cell imager (Zoe, BioRad, USA).

2.4 Antifungal efficacy of CuI (WH) and CuI (H) particles

The antifungal activity of CuI (WH) and CuI (H) against *C. albicans* was evaluated.

2.4.1 Fungal culture and maintenance. *C. albicans* inoculum was cultured in SD broth and then incubated at 37 °C until reaching an OD of 0.1. An inoculum of 0.5 McFarland standards, diluted in SD broth, was used for further antifungal experiments.³⁰

2.4.2 Evaluation of antifungal activity using MTT assay. In a 96-well plate, 100 μL of cultures (triplicates) in a 96-well plate were treated with CuI (WH) and CuI (H) at varying concentrations



of $25 \mu\text{g mL}^{-1}$ to $250 \mu\text{g mL}^{-1}$ along with the controls containing only SD broth and incubated at 37°C for 24 hours. After 24 hours of incubation, the cell viability of the fungus was quantified using the MTT assay.

2.4.3 Evaluation of antifungal activity using spot formation assay.

The antifungal studies of CuI (H) and CuI (WH) were performed using *C. albicans*. Briefly, $100 \mu\text{L}$ of *C. albicans* was treated with $100 \mu\text{g mL}^{-1}$, $150 \mu\text{g mL}^{-1}$ and $200 \mu\text{g mL}^{-1}$ of CuI (H) and CuI (WH) in 96-well plates and incubated at 37°C for 48 h. Upon incubation, a spot formation assay was performed. Briefly, $10 \mu\text{L}$ of 8-fold serial dilutions of treated and control samples (10 to 10^{-7}) from the 96-well plates were taken and spotted on SD agar plates. After 24 hours of incubation at 37°C , the difference in spot formation was evaluated.³⁴

2.4.4 Evaluation of antifungal activity using calcofluor white staining.

Briefly, *C. albicans* culture in a 96-well plate was treated with $150 \mu\text{g mL}^{-1}$ of CuI (WH) and CuI (H) along with the control and incubated at 37°C for 24 h. $10 \mu\text{L}$ of the culture, dropped onto a clean glass slide, was stained with calcofluor white stain and further fixed with 10% KOH solution. The samples were then mounted using a coverslip and imaged using a live cell imager.^{35,36}

2.5 Antiviral efficacy of CuI (WH) and CuI (H) particles

2.5.1 Culturing and maintenance of lambda phage (Φ).

The bacteriophage lambda (ATCC 23724-B2) was received as a gift sample from Dr Manjula Reddy, CSIR-CCMB, Hyderabad, India. The host strain *E. coli* C600 (ATCC 23724) was used to transmit the bacteriophage lambda (ATCC 23724-B2). This *E. coli* C600 was cultured in 10 mL of LB broth supplemented with 0.4% maltose at 37°C overnight to make a compatible host for bacteriophage. In the presence of 5 mM MgSO_4 , 0.1 mL of phage lysate (titer value 10^9 PFU mL^{-1}) was added to 1 mL of the overnight-grown *E. coli* C600 culture (1.0 OD), and the mixture was incubated for 20 h for infection. Then, it was transferred into a side arm flask containing 50–100 mL of LB broth with 5 mM MgSO_4 . The above mixture was then stirred at 280 rpm at 37°C for 6 to 8 hours to induce lysis. After that, the lysate was added with chloroform and subjected to centrifugation. The phage suspension-containing supernatant was collected and kept in chloroform at 4°C . Phage population was quantified using a plaque formation assay.

2.5.2 Evaluation of antiviral activity using plaque formation assay.

The antiviral activity of the synthesised CuI (WH) and CuI (H) was evaluated using plaque formation assay. Bacteriophage lambda cultures containing 10^5 PFU mL^{-1} in suspension buffer were divided into aliquots and incubated for 24 hours at 37°C with $50 \mu\text{g mL}^{-1}$ to $200 \mu\text{g mL}^{-1}$ of CuI (H) and CuI (WH), as well as an untreated control. Samples were diluted to obtain countable plaques of about 30–300, for which 0.1 mL each of the test and control samples were added to 0.1 mL of overnight cultured *E. coli* C600, mixed with 3 mL of melted soft agar, and then immediately poured onto the surface of a LB agar Petri plate containing 5 mM MgSO_4 . Plates were incubated for 18 hours and at 37°C , and the resulting plaques were counted. After counting the number of plaques in each plate for CuI

(WH), CuI (H), and controls in triplicate, the quantitative analysis was done.^{30,37}

2.6 Antibacterial efficacy of CuI (WH) and CuI (H) against MDR *E. coli*

The MDR *E. coli* (MCC 3671) was obtained from MTCC, India. All the experiments with MDR *E. coli* were performed under BSL-2 (Biosafety Level-2) facility. MDR *E. coli* was cultured using a similar protocol used to maintain *E. coli* and obtained 0.1 OD culture for experimental investigation.

The effect of CuI (H) and CuI (WH) on MDR *E. coli* was determined using MTT assay. For which, $100 \mu\text{L}$ of MDR *E. coli* culture was treated with media containing CuI (WH) and CuI (H) at concentrations from $25 \mu\text{g mL}^{-1}$ to $100 \mu\text{g mL}^{-1}$ and control treated with broth without any particles. Both treated and control were incubated at 37°C for 24 h. After incubation, the percentage of cell viability was measured using a microplate reader at 570 nm.

The effect was also qualitatively determined using AO staining and a fluorescence microscope. For which, $50 \mu\text{g mL}^{-1}$ concentration of CuI (WH) and CuI (H) treated MDR *E. coli* and control were stained using the aforementioned AO staining protocols and imaged under blue light using a fluorescence microscope.

2.7 Determining the effect of CuI (WH) and CuI (H) on normal and cancer cell lines

2.7.1 Cell culture and maintenance. Mice fibroblast cell line (L929), murine melanoma cell line (B16), murine triple-negative breast carcinoma cell line (4T1), human lung adenocarcinoma cell line (A549), and human colorectal carcinoma cell line (HCT116) were obtained from the National Centre for Cell Sciences, NCCS, Pune, India. The cell lines were cultured and maintained in RPMI and DMEM medium supplemented with 10% (v/v) FBS, and 100 U mL^{-1} streptomycin/penicillin, in a humidified incubator at 37°C containing 5% CO_2 .

2.7.2 Evaluating the effect of CuI (WH) and CuI (H) on cell viability. First, the effect of synthesised CuI (H) on cell viability of non-cancerous cells (L929) and different cancer cell lines (4T1, A549, HCT116 and B16) was determined using MTT assay. For which, $6-7 \times 10^3$ cells per well of each cell line were seeded in a 96-well plate. Upon attachment, cells were treated with 10 to $60 \mu\text{g mL}^{-1}$ concentration of CuI (H) and control treated with media without CuI (H). Both treated and control were incubated at 37°C for 24 h. After incubation, the percentage of cell viability was measured using a microplate reader at 570 nm.

Similarly, the effect of CuI (H) compared to CuI (WH) was determined using the B16 cell line. B16 cells were treated with both types of particles at concentrations of 10 to $60 \mu\text{g mL}^{-1}$. FDA and PI staining was used for qualitative analysis.³⁸

So far, several studies have reported the degradation of metallic nano-/microparticles to release ions upon interaction with cells or bacterial cultures. These released ions were reported to enter into the cells or bacteria *via* endocytosis or through ionic channels and commence the antiproliferative activity by damaging genetic material, active proteins or by generating reactive oxygen



species.^{39,40} In the present study, the degradation of CuI (H) upon interaction with cells or bacterial culture was determined by measuring and observing the change in the intrinsic fluorescence of CuI (H). For the same reason, first we incubated CuI (H) with *E. coli* culture at 37 °C and the change in fluorescence of CuI (H) at 0 h, 12 h, and 24 h was quantified using a Tecan plate reader. CuI (H) in PBS was used as control.

Similarly, the change in fluorescence of CuI (H) on interaction with B16 cells was observed using fluorescence microscopy. For which, we incubated CuI (H) with B16 cells at 37 °C and observed the change in fluorescence at 0 h, 12 h, and 24 h. CuI (H) in PBS incubated at 37 °C was used as control.

2.8 Evaluating the effect of CuI (WH) and CuI (H) on the migration of B16 and L929 cells

The effect of CuI (WH) and CuI (H) on the migration of cells was evaluated using *in vitro* wound healing assay. Briefly, B16 and L929 cell lines were seeded in a 24-well plate at a count of 1×10^5 cells per well. After attachment and reaching sufficient confluence, a wound was created in the cells using a micropipette. The cells were treated with CuI (WH) and CuI (H) at 50 $\mu\text{g mL}^{-1}$ concentration. The effect on the migration of cells was observed using a microscope at 12 h and 24 h. The experiment was performed in triplicate, and the % migration was calculated using ImageJ software with macros plugin to quantify the migration as per the reported procedure.^{41,42}

2.9 Determining CuI (H) stability and its application as a surface steriliser

CuI (H) stability was determined by suspending CuI (H) in Milli-Q (MQ) water exposed to daylight, and its fluorescence emission was measured for the 0th, 15th, and 30th day of post-suspension. After the 30th day, suspended CuI (H) particles were drop-cast on a silicon wafer and imaged using FE-SEM. The surface sterilising property of CuI (H) was determined by spreading MH broth-suspended CuI (H) onto a glass slide and comparing it with positive control of MH broth alone spread on the glass slide. Both the glass slides were kept under daylight and exposed to air for 15 days. After 15 days, the glass slide surface was swabbed using cotton swabs, inoculated in MH broth, and incubated at 37 °C for 30 min under stirring. Then, the inoculum was spread over the MH agar Petri dish and further incubated for 16 hours at 37 °C. After the incubation, colonies formed on the agar plate were captured using camera (Schematic.2).

3. Results and discussion

3.1 Synthesis and characterisation of CuI (WH) and CuI (H)

In the current study, we have synthesised PAA-coated CuI using chemical precipitation followed by hydrothermal processes. CuI (WH) synthesised without the hydrothermal method displayed large irregularly shaped particles with a size ranging from 0.8 μm to 2 μm (Fig. 1(a)). Due to the low zeta potential of -2.5 mV (Fig. 1(f)), CuI (WH) exhibited poor stability, thereby forming large clumps as seen upon FE-SEM analysis (Fig. 1(b)).

Hydrothermal treatment of CuI (WH) resulted in the formation of CuI (H) microhexagons, which displayed a smaller size (0.6–0.8 μm) with a higher zeta potential forming well-dispersed microparticles (Fig. 1(e–g)). Several studies have reported the synthesis of nano-/microparticles using hydrothermal method (at higher temperature) displayed significantly better surface physicochemical properties compared to the particles synthesized using chemical precipitation method at room temperature. In this perspective, the synthesized CuI (H) exhibited higher dispersibility and stability, which is evident from its higher zeta potential and SEM imaging compared to CuI (WH) synthesized at room temperature.^{43–46} EDS analysis also confirmed the presence of copper and iodine in CuI (H) (Fig. S1, ESI†). Also, CuI (H) showed peak absorption at 285 nm and emission at 715 nm when excited using 385 nm. Under UV light (365 nm), CuI (H) displayed bright red fluorescence, whereas no fluorescence was observed for CuI (WH) (Fig. 1(c) and (d)). CuI synthesised using the hydrothermal process without PAA displayed a lesser fluorescence emission intensity and poor aqueous dispersibility (Fig. S2, ESI†). Hence, we have excluded it from further experimental investigation. CuI (H) synthesised using a hydrothermal process displayed superior properties compared to CuI (WH) with respect to its size, shape, and surface charge. Hence, hydrothermal treatment and PAA coating had imparted significant characteristics to CuI, which will be helpful in various biological applications.

3.2 Antibacterial efficacy of CuI (WH) and CuI (H)

The antibacterial efficacy of CuI (H) and CuI (WH) against *E. coli* and *S. aureus* cultures was determined using MTT assay, spot formation assay, and AO staining. From the MTT assay, it was observed that the *E. coli* culture displayed a 50% decrease in growth at 50 $\mu\text{g mL}^{-1}$ concentration of CuI (H), while the percentage death of *E. coli* at the same concentration of CuI (WH) was found to be 22% (Fig. 2(a)). The IC₅₀ value of CuI (H) against *E. coli* was found to be less than that of earlier reported copper-based nanoparticles (60 $\mu\text{g mL}^{-1}$).⁴⁷

Similarly, the IC₅₀ value of CuI (H) against *S. aureus* was found to be 200 $\mu\text{g mL}^{-1}$, while at the same concentration of CuI (WH), the % death of *S. aureus* was about 25% (Fig. 3(a)). Same results were reflected in the spot formation assay (Fig. 2(b) and 3(b)). As the concentration of CuI (H) increased, the spot size decreased in every dilution. However, in the case of CuI (WH)-treated bacteria, the decrease in spot size was insignificant compared to the control. The qualitative visualisation of the inhibitory effect of CuI (WH) and CuI (H) against both the cultures was observed using AO stain. It was found that the control and CuI (WH)-treated group displayed more highly fluorescent colonies in comparison to the CuI (H) group (Fig. 2(c) and (d) for *E. coli* and Fig. 3(c) and (d) for *S. aureus*). As AO is an intercalating agent staining DNA, the control and CuI (WH)-treated group displayed higher bacterial viability and thus DNA content, which resulted in more retention of AO and hence a higher number of fluorescent colonies under a fluorescence microscope compared to the CuI (H)-treated bacteria. Therefore, CuI (H) could be a potential antibacterial material, showing activity against both Gram-positive and Gram-negative bacterial strains.






Fig. 1 Synthesis and characterization of CuI (WH) and CuI (H). (a) Hydrodynamic diameter of CuI (WH). (b) FE-SEM analysis of CuI (WH). (c) UV-visible absorption spectra of CuCl₂, CuI (WH), and CuI (H). (d) Fluorescence spectra of CuI (WH) and CuI (H) and inset showing images under white light and UV light (365 nm) of CuI (WH) (left) and CuI (H) (right). (e) Hydrodynamic diameter of CuI (H). (f) Zeta potential of CuI (WH) and CuI (H). (g) FE-SEM images of CuI (H).

3.3 Antifungal efficacy of CuI (H) in comparison to CuI (WH)

Antifungal efficacy of CuI (H) and CuI (WH) against *C. albicans* culture was determined using MTT assay, spot formation assay, and calcofluor white staining. After 48 h of incubation, it was

observed that the *C. albicans* culture displayed 50% decrease in growth at 150 $\mu\text{g mL}^{-1}$ concentration of CuI (H), while at the same concentration of CuI (WH) it was found to be 24% (Fig. 4(a)). Similar results were reflected in the spot formation






Fig. 2 Antibacterial activity of CuI (WH) and CuI (H) against *E. coli*. (a) MTT assay, (b) spot assay, and (c) AO staining. (d) Fluorescence quantification of AO staining. $p < 0.05$, $****p < 0.0001$, $**p < 0.01$. Scalebar: 100 μm (left) and 33 μm (right).

assay (Fig. 4(b)). The spot size for the CuI (H)-treated sample was significantly decreased with increasing concentration at each dilution. In CuI (WH)-treated cells, the decrease in spot size was insignificant compared to the control. Similarly, the morphological effect on *C. albicans* after the treatment with CuI (H) and CuI (WH) was observed using a calcofluor white stain, when imaged under a fluorescence microscope. The untreated control sample displayed a very large number of colonies with well-defined hyphae stained in blue colour, whereas the CuI (WH)-treated culture showed fewer patches with improper hyphae, and the CuI (H)-treated sample showed no notable fungal patches

without any hyphae (Fig. 4(c) and (d)). Therefore, it is evident that CuI (H) could qualify as a potential antifungal material.

3.4 Antiviral efficacy of CuI (H) in comparison to CuI (WH)

The effect of CuI (WH) and CuI (H) against bacteriophage lambda growth was evaluated using plaque formation assays. Bacteriophages were treated with same concentrations of CuI (WH) and CuI (H) microparticles and then were further allowed to infect *E. coli* C600.

Upon 18 hours of incubation at 37 °C, a significant difference in the number of plaques formed was observed by varying




Fig. 3 Antibacterial activity of Cul (WH) and Cul (H) against *S. aureus*. (a) MTT assay, (b) spot assay and (c) AO staining. (d) Fluorescence quantification of AO staining. $p < 0.05$, $**p < 0.01$, $****p < 0.0001$, ns (not significant). Scalebar: 100 μm (left) and 33 μm (right).

the CuI (WH) and CuI (H) concentrations. At the same concentrations of CuI (WH) and CuI (H), the number of plaques formed was almost triple in the case of CuI (WH) in comparison to CuI (H) (Fig. 5(a)). Quantitative analysis was done by counting the number of plaques in triplicate. It was observed that at 50 $\mu\text{g mL}^{-1}$ concentration of CuI (H) the number of plaques was almost 50% fewer than for the CuI (WH)-treated sample (Fig. 5(b)). CuI (H) significantly reduced the growth of bacteriophage lambda. Therefore, CuI (H) could be used as potential antiviral material.

3.5 Antibacterial efficacy of CuI (WH) and CuI (H) against MDR *E. coli*

After evaluating the efficiency of CuI (H) in inhibiting non-drug-resistant bacteria, we further determined the antiproliferative efficiency of CuI (H) against MDR *E. coli*. CuI (H) displayed 50% inhibition of MDR *E. coli* at 50 $\mu\text{g mL}^{-1}$. In comparison, at the same concentration of CuI (WH), the inhibition was around 20% (Fig. 6(a)). Similarly, we qualitatively evaluated the effect of CuI (H) using AO staining. It was found that CuI (H)-treated bacteria displayed significantly less fluorescent colonies compared to control




Fig. 4 Antifungal activity of CuI (WH) and CuI (H) against *C. albicans*. (a) MTT assay, (b) spot assay, and (c) calcofluor white staining. (d) Fluorescence quantification of calcofluor white staining. $p < 0.05$, $**p < 0.01$, $***p < 0.001$, ns (not significant). Scalebar: 100 μm (left) and 33 μm (right).

and CuI (WH)-treated bacteria (Fig. 6(b) and (c)). CuI (H) is found to be highly effective against MDR *E. coli* growth. Therefore, CuI (H) could be beneficial in treating MDR strain infections.

3.6 Anticancer efficacy of CuI (WH) and CuI (H)

The biocompatibility and cytotoxicity of CuI (WH) and CuI (H) against non-cancerous and cancer cell lines were determined using MTT assay and qualitative analysis was done using FDI/PI staining. The IC_{50} value for CuI (H) against cancer cells (HCT116, 4T1, A549, and B16) was found to be 40 $\mu\text{g mL}^{-1}$ (Fig. S3(b-d), ESI†). At the same concentration of CuI (H) used to treat L929 cells, the % of live cells was found to be more than 75% (Fig. S3(a), ESI†). This indicates that CuI (H) displays cytotoxicity against cancer cells, and, at the same, it is compatible with non-cancerous cells (Fig. 7(a)).

As the size of CuI (H) is micrometric, using it within the body will have certain drawbacks, such as low tumour accumulation or it may block small blood vessels, leading to detrimental side effects. CuI (H) could be used to treat surface infections and superficial tumors, such as melanoma, to avoid such side effects. With this perspective, we have evaluated the cytotoxic efficacy of CuI (H) in comparison to CuI (WH) at different concentrations (10–60 $\mu\text{g mL}^{-1}$). CuI (H) was found to be more effective in inhibiting the growth of B16 cells compared to CuI (WH), and IC_{50} values were 40 $\mu\text{g mL}^{-1}$ and 60 $\mu\text{g mL}^{-1}$, respectively (Fig. 7(b)).

The qualitative visualisation of the anticancer efficacy of CuI (WH) and CuI (H) against B16 cells was observed by live/dead staining using FDI/PI stains. It was found that the control and CuI (WH)-treated group displayed a higher green fluorescence (FDI) in comparison to the CuI (H) group. At the same time,




Fig. 5 Antiviral activity of CuI (WH) and CuI (H) against bacteriophage lambda. (a) Qualitative analysis by plaque formation assay. (b) Quantitative analysis. $p < 0.05$, $****p < 0.0001$; ns: non-significant.




Fig. 6 Antibacterial activity of CuI (WH) and CuI (H) against MDR *E. coli*. (a) MTT assay. (b) AO staining. (c) Fluorescence quantification of AO staining. $p < 0.05$, $***p < 0.001$, ns (not significant). Scalebar: 100 μ m.

more red fluorescence (PI) was observed in CuI (H)-treated cells in comparison to control and CuI (WH)-treated cells validating the quantitative results obtained using MTT assay (Fig. 7(c)). From the obtained results, it is evident that CuI (H) is more potent in inhibiting the growth of cancer cells and biocompatible towards non-cancerous cells. Therefore, CuI (H) could represent a potent anticancer material.

Metallic nanoparticles, primarily composed of gold (Au), silver (Ag), or copper (Cu), exhibit potent antimicrobial properties. The mechanism behind the antibacterial efficacy of suspended metallic particles is not well understood. According to recent reports, the antibacterial activity is associated with the release of ions from the particles upon interaction with cells or the microbes.

These released ions enter plasma membranes through endocytosis or *via* ion channels. Upon entry, metallic ions cause a series of effects by damaging proteins and genetic materials and causing generation of reactive oxygen species leading to cell death.^{39,40} Previous studies have also reported CuI nanoparticles which exhibit greater efficacy against Gram-negative bacteria in comparison to Gram-positive bacteria, because of more negative charge on the surface leading to strong attraction towards the released positive ions (Cu^{2+}).^{48,49}

In accordance with the reported studies, we have found similar results. From the determination of change in fluorescence of CuI (H) upon incubation with B16 and *E. coli* culture, there was a significant loss of fluorescence intensity after 24 h, whereas in PBS no significant change in CuI (H) fluorescence was observed (Fig. S4(a), ESI†). The obtained results validate those of previously reported studies.

3.7 Evaluating the effect of CuI (WH) and CuI (H) on the migration of B16 and L929 cells

Cell migration is a major contributing factor for transformation of benign tumours into malignant ones. Inhibition of cellular migration and subsequent metastatic growth in malignant tumours is more challenging. We have evaluated the effect of CuI (H) ($50 \mu\text{g mL}^{-1}$) on the migration of B16 and L929 cells in comparison to CuI (WH) ($50 \mu\text{g mL}^{-1}$) and control at 12 h and 24 h. At 12 h, it was observed that CuI (WH)-treated and untreated control cells displayed migration of 35% and 83%, respectively. In comparison, CuI (H)-treated cells displayed migration of only 19%. After 24 h, the migration in CuI (WH)-treated and untreated control cells was about 88% and 100%, respectively, while in CuI (H)-treated cells it was around 29% (Fig. 8(a) and (b)). Therefore, CuI (H) microhexagons are more potent in inhibiting cancer cell migration, simultaneously not affecting the migration of non-cancerous cells (L929) (Fig. S5, ESI†), which could be useful in preventing development of malignant squamous cell carcinoma.






Fig. 7 Effect of CuI (WH) and CuI (H) against non-cancerous and cancer cells. (a) MTT assay in L929 cells and 4T1, A549, HCT116, and B16 cells. (b) MTT assay in B16 cells with different concentrations of CuI (WH) and CuI (H). (c) Live/dead staining of B16 cells. $p < 0.05$, $****p < 0.0001$, $***p < 0.001$. Scalebar: 100 μ m.

3.8 Determining the stability of CuI (H) and its application as a surface steriliser


The aqueous stability of CuI (H) for 30 days was evaluated using a fluorescence spectrophotometer and FE-SEM. The fluorescence intensity of 30 days aqueous suspended CuI (H) was decreased by only 18% in comparison to the 0th day, while the shape of CuI (H) was retained as same as that of the 0th day (Fig. 9(a) and (b)). Similarly, slides spread with MH broth-suspended CuI (H) and MH broth alone exposed to daylight and air for 15 days were used to determine the surface disinfectant property of CuI (H) (Fig. 9(c)). The number of colonies in the CuI (H) inoculum-spread Petri dish were significantly fewer in comparison to the MH broth inoculum-spread Petri dish

(Fig. 9(d)). From the results, it is evident that CuI (H) retains its stability in an aqueous solution even under daylight and retains its antiproliferative property. Therefore, CuI (H) could be used as an efficient surface disinfectant material in microbial infection-prone areas.

4. Conclusion

Microbial infections are a continuing threat to human health. The use of antibiotics to treat microbial infections is known to elicit microbial resistance, which further attenuates the efficiency of treatment. Recent reports also suggested the emergence of microbial infections in tumour regions, which further

(a)



(b)




Fig. 8 The effect of CuI (WH) and CuI (H) on cell migration of B16 cells. (a) Qualitative. (b) Quantitative. $p < 0.05$, $****p < 0.0001$, $***p < 0.001$. Scalebar: 100 μ m.

aggravates tumour-related complications. So, developing a treatment modality effective in treating microbial infections and inhibiting cancer growth without inducing resistance will be of great importance. In the present study, CuI microparticles were synthesised using the chemical precipitation method followed by hydrothermal reaction. The high temperature involved in the hydrothermal process as well as PAA coating played a significant role in forming well-dispersed and uniform-sized CuI (H)

microhexagons. Studies have reported that smaller sized and higher zeta potential particles will display greater stability and cell attraction, hence significantly higher therapeutic efficacy.⁵⁰⁻⁵² Similarly, the smaller size and higher zeta potential (-16 mV) of CuI (H) compared to CuI (WH) led to a higher stability and antiproliferative activity against microbial culture, including resistant strain (*E. coli*), viral and cancer cells in comparison to CuI (WH). CuI (H) microparticles also retained their structure and




Fig. 9 Stability of Cul (H) and its use for surface sterilization. (a) Fluorescence emission spectra of Cul (H) for 0th, 15th, and 30th day. (b) FE-SEM analysis of 30 days aqueous suspended Cul (H). (c) A schematic representation of Cul (H) in surface sterilization. (d) Qualitative representation of 15 days daylight- and air-exposed slides spread with MH broth and Cul (H) (slides under UV lamp) and MH agar plates spread with respective inoculum.

fluorescence in an aqueous solution for 30 days and found to be effective antiproliferative agent against microbial growth. From the obtained results, it can be deduced that CuI (H) could represent a potential material for treating surface microbial infections and

superficial tumors, such as melanoma. CuI (H) could also be used as a surface disinfectant in microbial infection-prone areas. However, a significant *in vivo* analysis of the antimicrobial property of CuI (H) is required for a potential clinical translation.

Author contributions

Sunil Venkanna Pogu: conceptualization, investigation, experimental studies, writing – original draft. Dokkari Nagalaxmi Yadav: investigation, experimental studies, writing – original draft. Sri Amruthaa Sankaranarayanan: experimental studies. Rupali Srivastava: experimental studies. Shashidhar Thatikonda: supervision, fund acquisition. Aravind Kumar Rengan: conceptualization, supervision, fund acquisition, project administration, review.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Acknowledgements

The authors would like to acknowledge MHRD IMPRINT (4291), ICMR (no. 35/1/2020-GIA/Nano/BMS), ICMR-CoE grant, DST-AMT (DST/TDT/AMT/2017/227), SERB-CRG (CRG/2020/005069), IITB/BME/SOCH3 project grants, and SUPRA (SPR/2022/230). The authors gratefully acknowledge Dr Manjula Reddy, Chief Scientist, CSIR-Hyderabad for providing the bacteriophage lambda (ATCC 23724-B2) and *E. coli* cultures. A fellowship from the Department of Biotechnology, Ministry of Science & Technology, Government of India (DBT/2020/IIT-H/1356) is gratefully acknowledged by author S. V. P. Author D. N. Y. would like to gratefully acknowledge DST INSPIRE (DST/INSPIRE/03/2019/001517) for funding her fellowship. Author S. A. S. would like to gratefully acknowledge MoE-PMRF (ID 2000832) for funding her fellowship. The authors would also like to acknowledge their labmate Himasree Buddhiraju. Licensed version of BioRender.com was used for preparing graphical abstract & schematic.

References

- 1 A. Shakir, D. Abate, F. Tebeje and F. Weledegebreal, *Infect. Drug Resist.*, 2021, **14**, 4629–4639.
- 2 R. E. Mengesha, B. G. S. Kasa, M. Saravanan, D. F. Berhe and A. G. Wasihun, *BMC Res. Notes*, 2014, **7**, 4–9.
- 3 A. E. Ghenea, R. Ciobătă, A. I. Drocaş, E. N. Țieranu, C. M. Vasile, A. Moroşanu, C. G. Țieranu, A. I. Salan, M. Popescu, A. Turculeanu, V. Padureanu, A. L. Udrîştoi, D. Calina, D. Cârțu and O. M. Zlatian, *Antibiotics*, 2021, **10**, 868.
- 4 S. Bungau, D. M. Tit, T. Behl, L. Aleya and D. C. Zaha, *Curr. Opin. Environ. Sci. Health*, 2021, **19**, 100224.
- 5 S. Qin, W. Xiao, C. Zhou, Q. Pu, X. Deng, L. Lan, H. Liang, X. Song and M. Wu, *Signal Transduction Target. Ther.*, 2022, **7**, 1–27.
- 6 Z. Tang, B. Song, W. Zhang, L. Guo and J. Yuan, *Anal. Chem.*, 2019, **91**, 14019–14028.
- 7 E. Avershina, V. Shapovalova and G. Shipulin, *Front. Microbiol.*, 2021, **12**, 2044.
- 8 C. J. Murray, K. S. Ikuta, F. Sharara, L. Swetschinski, G. Robles Aguilar, A. Gray, C. Han, C. Bisignano, P. Rao, E. Wool, S. C. Johnson, A. J. Browne, M. G. Chipeta, F. Fell, S. Hackett, G. Haines-Woodhouse, B. H. Kashef Hamadani, E. A. P. Kumaran, B. McManigal, R. Agarwal, S. Akech, S. Albertson, J. Amuasi, J. Andrews, A. Aravkin, E. Ashley, F. Bailey, S. Baker, B. Basnyat, A. Bekker, R. Bender, A. Bethou, J. Bielicki, S. Boonkasidecha, J. Bukosia, C. Carvalheiro, C. Castañeda-Orjuela, V. Chansamouth, S. Chaurasia, S. Chiurchiù, F. Chowdhury, A. J. Cook, B. Cooper, T. R. Cressey, E. Criollo-Mora, M. Cunningham, S. Darboe, N. P. J. Day, M. De Luca, K. Dokova, A. Dramowski, S. J. Dunachie, T. Eckmanns, D. Eibach, A. Emami, N. Feasey, N. Fisher-Pearson, K. Forrest, D. Garrett, P. Gastmeier, A. Z. Giref, R. C. Greer, V. Gupta, S. Haller, A. Haselbeck, S. I. Hay, M. Holm, S. Hopkins, K. C. Iregbu, J. Jacobs, D. Jarovsky, F. Javanmardi, M. Khorana, N. Kissoon, E. Kobeissi, T. Kostyanev, F. Krapp, R. Krumkamp, A. Kumar, H. H. Kyu, C. Lim, D. Limmathuotsakul, M. J. Loftus, M. Lunn, J. Ma, N. Mturi, T. Munera-Huertas, P. Musicha, M. M. Mussi-Pinhata, T. Nakamura, R. Nanavati, S. Nangia, P. Newton, C. Ngoun, A. Novotney, D. Nwakanma, C. W. Obiero, A. Olivas-Martinez, P. Olliaro, E. Ooko, E. Ortiz-Brizuela, A. Y. Peleg, C. Perrone, N. Plakkal, A. Ponce-de-Leon, M. Raad, T. Ramdin, A. Riddell, T. Roberts, J. V. Robotham, A. Roca, K. E. Rudd, N. Russell, J. Schnall, J. A. G. Scott, M. Shivamallappa, J. Sifuentes-Osornio, N. Steenkeste, A. J. Stewardson, T. Stoeva, N. Tasak, A. Thaiprakong, G. Thwaites, C. Turner, P. Turner, H. R. van Doorn, S. Velaphi, A. Vongpradith, H. Vu, T. Walsh, S. Waner, T. Wangrangsimakul, T. Wozniak, P. Zheng, B. Sartorius, A. D. Lopez, A. Stergachis, C. Moore, C. Dolecek and M. Naghavi, *Lancet*, 2022, **399**, 629–655.
- 9 N. S. Alharbi, J. M. Khaled, S. Kadaikunnan, A. S. Alobaidi, A. H. Sharafaddin, S. A. Alyahya, T. N. Almanaa, M. A. Alsughayier and M. R. Shehu, *Saudi J. Biol. Sci.*, 2019, **26**, 1557–1562.
- 10 B. W. J. H. Penninx, M. E. Benros, R. S. Klein and C. H. Vinkers, *Nat. Med.*, 2022, **28**, 2027–2037.
- 11 F. Bray, M. Laversanne, E. Weiderpass and I. Soerjomataram, *Cancer*, 2021, **127**, 3029–3030.
- 12 A. Krueger, J. Zaugg, S. Chisholm, R. Linedale, N. Lachner, S. M. Teoh, Z. K. Tuong, S. W. Lukowski, M. Morrison, H. P. Soyer, P. Hugenholtz, M. M. Hill and I. H. Frazer, *Front. Microbiol.*, 2022, **12**, 1–17.
- 13 B. Joob and V. Wiwanitkit, *Asian Pac. J. Trop. Dis.*, 2014, **4**, 204–206.
- 14 Y. Wen, J. Hu, J. Liu and M. Li, *Chem. Mater.*, 2021, **33**, 7089–7099.
- 15 H. Zhang and X. B. Yin, *ACS Appl. Mater. Interfaces*, 2022, **14**, 26528–26535.
- 16 M. M. Mamun, A. J. Sorinolu, M. Munir and E. P. Vejerano, *Front. Chem.*, 2021, **9**, 1–23.
- 17 A. Singh, A. Ahmed, A. K. Keshri, N. Arora, F. Anjum, S. S. Rawat and A. Prasad, *Bionanoscience*, 2021, **11**, 637–642.
- 18 J. Salvo and C. Sandoval, *Burns Trauma*, 2022, **10**, DOI: [10.1093/burnst/tkab047](https://doi.org/10.1093/burnst/tkab047).
- 19 X. Zhang, L. Detering, D. Sultan, H. Luehmann, L. Li, G. S. Heo, X. Zhang, L. Lou, P. M. Grierson, S. Greco, M. Ruzinova, R. Laforest, F. Dehdashti, K. H. Lim and Y. Liu, *ACS Nano*, 2021, **15**, 1186–1198.



20 K. Kirakci, D. Bůžek, P. Peer, V. Liška, J. Mosinger, I. Křížová, M. Kloda, S. Ondrušová, K. Lang and J. Demel, *ACS Appl. Nano Mater.*, 2022, **5**, 1244–1251.

21 W. Lu, S. Song, Y. Qian, Q. Liu, P. Li, Y. Han, J. Zhang, J. Xu, J. Sun and A. Wu, *ACS Nano*, 2021, **15**, 2933–2946.

22 D. Verma Atul, *Certain distance degree based Topol. indices Zeolite LTA Fram.*, 2018, 11–14.

23 B. L. Cline, W. Jiang, C. Lee, Z. Cao, X. Yang, S. Zhan, H. Chong, T. Zhang, Z. Han, X. Wu, L. Yao, H. Wang, W. Zhang, Z. Li and J. Xie, *ACS Nano*, 2021, **15**, 17401–17411.

24 J. Yu, X. He, Q. Zhang, D. Zhou, Z. Wang and Y. Huang, *ACS Nano*, 2022, **16**, 6835–6846.

25 R. Khursheed, K. Dua, S. Vishwas, M. Gulati, N. K. Jha, G. M. Aldhafeeri, F. G. Alanazi, B. H. Goh, G. Gupta, K. R. Paudel, P. M. Hansbro, D. K. Chellappan and S. K. Singh, *Biomed. Pharmacother.*, 2022, **150**, 112951.

26 A. Cartwright, K. Jackson, C. Morgan, A. Anderson and D. W. Britt, *Agronomy*, 2020, **10**, 1–20.

27 M. C. Crisan, M. Teodora and M. Lucian, *Appl. Sci.*, 2021, **12**, 141.

28 T. Han, Z. Ma and D. Wang, *ACS Macro Lett.*, 2021, **10**, 354–358.

29 Y. Zhou, M. lü, G. Zhou, S. Wang and S. Wang, *Mater. Lett.*, 2006, **60**, 2184–2186.

30 T. Appidi, G. Ravichandran, S. V. Mudigunda, A. Thomas, A. B. Jogdand, S. Kishen, K. Subramaniyam, N. Emani, G. Prabusankar and A. K. Rengan, *Mater. Today Commun.*, 2021, **29**, 102987.

31 S. B. Alvi, P. S. Rajalakshmi, A. Jogdand, A. Y. Sanjay, B. Veeresh, R. John and A. K. Rengan, *Biomater. Sci.*, 2021, **9**, 1421–1430.

32 S. Sharma, J. Acharya, M. R. Banjara, P. Ghimire and A. Singh, *BMC Res. Notes*, 2020, **13**, 1–5.

33 F. Dharul Salam, M. Nadar Vinita, P. Puja, S. Prakash, R. Yuvakkumar and P. Kumar, *Mater. Lett.*, 2020, **261**, 126998.

34 D. N. Yadav, S. A. Sankaranarayanan, A. M. Thanekar and A. K. Rengan, *Mater. Today Nano*, 2023, 100348.

35 P. Alekhya, C. Aruna Sunder and Prathiba, *Avicenna J. Clin. Microbiol. Infect.*, 2020, **7**, 124–128.

36 A. Ajdidi, G. Sheehan, K. A. Elteen and K. Kavanagh, *J. Med. Microbiol.*, 2019, **68**, 1497–1506.

37 S. Chhibber, P. Kaur and V. S. Gondil, *J. Virol. Methods*, 2018, **262**, 1–5.

38 T. Appidi, D. B. Pemmaraju, R. A. Khan, S. B. Alvi, R. Srivastava, M. Pal, N. Khan and A. K. Rengan, *Nanoscale*, 2020, **12**, 2028–2039.

39 Z. Xiu, J. Ma and P. J. J. Alvarez, *Environ. Sci. Technol.*, 2011, **45**, 9003–9008.

40 C. Gunawan, W. Y. Teoh, C. P. Marquis and R. Amal, *ACS Nano*, 2011, 7214–7225.

41 J. Pijuan, C. Barceló, D. F. Moreno, O. Maiques, P. Sisó, R. M. Martí, A. Macià and A. Panosa, *Front. Cell Dev. Biol.*, 2019, **7**, 1–16.

42 J. P. S. Nunes and A. A. M. Dias, *Biotechniques*, 2017, **62**, 175–179.

43 E. N. Zare, X. Zheng, P. Makvandi, H. Gheybi, R. Sartorius, C. K. Y. Yiu, M. Adeli, A. Wu, A. Zarrabi, R. S. Varma and F. R. Tay, *Small*, 2021, **17**, 1–31.

44 A. Lassenberger, T. A. Grünwald, P. D. J. Van Oostrum, H. Rennhofer, H. Amenitsch, R. Zirbs, H. C. Lichtenegger and E. Reimhult, *Chem. Mater.*, 2017, **29**, 4511–4522.

45 H. Xie, M. Hong, E. M. Hitz, X. Wang, M. Cui, D. J. Kline, M. R. Zachariah and L. Hu, *J. Am. Chem. Soc.*, 2020, **142**, 17364–17371.

46 H. Liu, H. Zhang, J. Wang and J. Wei, *Arabian J. Chem.*, 2020, **13**, 1011–1019.

47 S. S. Skeeters, A. C. Rosu, Divyanshi, J. Yang and K. Zhang, *ACS Appl. Mater. Interfaces*, 2020, **12**, 50203–50211.

48 A. Pramanik, D. Laha, D. Bhattacharya and P. Pramanik, *Colloids Surf., B*, 2012, **96**, 50–55.

49 I. P. Parkin, *Advances*, 2021, **11**, 18179–18186.

50 E. Fröhlich, *Int. J. Nanomed.*, 2012, **7**, 5577–5591.

51 L. E. Shi, Z. H. Li, W. Zheng, Y. F. Zhao, Y. F. Jin and Z. X. Tang, *Food Addit. Contam.: Part A*, 2014, **31**, 173–186.

52 K. P. Steckiewicz, J. Zwara, M. Jaskiewicz, S. Kowalski, W. Kamysz, A. Zaleska-Medynska and I. Inkielewicz-Stepniak, *Oxid. Med. Cell. Longevity*, 2019, **2019**, DOI: [10.1155/2019/6740325](https://doi.org/10.1155/2019/6740325).

